02:06 , May 11, 2018 |  BC Innovations  |  Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
07:00 , Oct 1, 2012 |  BioCentury  |  Finance

Valeant's eye chart

Valeant's eye chart With the acquisition of Visudyne verteporfin from QLT Inc. (TSX:QLT; NASDAQ:QLTI), Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) is once again betting it can resurrect an ophthalmic drug that had been left by...
00:18 , Mar 22, 2012 |  BC Extra  |  Politics & Policy

MEDCAC backs anti-VEGFs for DME

CMS's Medicare Evidence Development & Coverage Advisory Committee concluded on Wednesday that there is adequate evidence that anti-VEGF treatments for diabetic macular edema improve patient outcomes compared to management of DME without the targeted agents....
08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

Eyetech, Valeant Pharmaceuticals deal

Valeant will acquire Eyetech for an undisclosed upfront payment and potential milestones. Valeant will gain Macugen pegaptanib, a pegylated oligonucleotide aptamer that binds to VEGF-165 marketed in the U.S. to treat wet age-related macular degeneration...
08:00 , Feb 20, 2012 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones BioSante Pharmaceuticals Inc. (NASDAQ:BPAX) gained $0.21 (27%) to $0.97 on Wednesday after FDA approved an NDA from partner Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) for Bio-T-Gel to treat male hypogonadism. BioSante is eligible for...
01:48 , Feb 14, 2012 |  BC Extra  |  Company News

Valeant to acquire Eyetech

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) will acquire Eyetech Inc. (Palm Beach Gardens, Fla.) for an undisclosed upfront payment and potential milestones. Valeant will gain Macugen pegaptanib, a pegylated oligonucleotide aptamer that binds to VEGF-165...
07:00 , Oct 3, 2011 |  BioCentury  |  Finance

Few Cinderellas this time

Big caps suffered the least in a very ugly quarter. But that's not saying much: biotechs with market caps of more than $5 billion were still down 10% as a group in 3Q, while other...
07:00 , Aug 15, 2011 |  BC Week In Review  |  Company News

Gilead, Astellas infectious news

Gilead said FDA accepted the company's response to a warning letter issued last year over violations of cGMP regulations identified during an inspection of the company's San Dimas, Calif., manufacturing facility. Gilead said the issues...
07:00 , Jul 25, 2011 |  BC Week In Review  |  Clinical News

Macugen pegaptanib regulatory update

Pfizer withdrew an application to extend the label for Macugen pegaptanib in Europe to include visual impairment due to diabetic macular edema (DME). According to EMA, Pfizer made the decision after CHMP said the compound...
00:21 , Jul 20, 2011 |  BC Extra  |  Company News

Pfizer withdraws EU application for Macugen label extension

Pfizer Inc. (NYSE:PFE) withdrew an application to extend the label for Macugen pegaptanib in Europe to include visual impairment due to diabetic macular edema. According to EMA, Pfizer made the decision after CHMP said the...